(2023)
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study.
ESMO OPEN.
8,
6
(2023)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
ORAL ONCOLOGY.
147,
(2023)
Real-World Outcomes of Immunotherapy in Second- or Later-Line Non-Small Cell Lung Cancer with Actionable Genetic Alterations.
CANCERS.
15,
22
(2023)
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
CLINICAL CANCER RESEARCH.
29,
22
(2023)
A Phase II Study of Osimertinib in Patients with Advanced-Stage Non-Small Cell Lung Cancer following Prior Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR TKI) Therapy with EGFR and T790M Mutations Detected in Plasma Circulating Tumour DNA (PLASMA Study).
CANCERS.
15,
20
(2023)
Expanded Access Program Pralsetinib in Advanced Non-Small Cell Lung Cancer with Rearranged during Transfection (RET) Gene Rearrangement.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
LUNG CANCER.
184,
(2023)
Lazertinib Versus Gefitinib Tyrosine Kinase Inhibitors in Treatment-Naíve Patients With EGFR-Mutated Advanced NSCLC: Analysis of the Asian Subpopulation in LASER301.
JOURNAL OF THORACIC ONCOLOGY.
18,
10
(2023)
Phase II Trial of Combined Durvalumab Plus Tremelimumab with Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
CANCER RESEARCH AND TREATMENT.
55,
4
(2023)
Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non-Small-Cell Lung Cancer: Results From LASER301.
JOURNAL OF CLINICAL ONCOLOGY.
41,
26
(2023)
Early Clearance of Plasma Epidermal Growth Factor Receptor Mutations as a Predictor of Outcome on Osimertinib in Advanced Non-Small Cell Lung Cancer; Exploratory Analysis from AURA3 and FLAURA.
CLINICAL CANCER RESEARCH.
29,
17
(2023)
Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non–Small Cell Lung Cancer.
JOURNAL OF THORACIC ONCOLOGY.
18,
9
(2023)
Prognostic Significance of Volumetric Parameters Based on FDG PET/CT in Patients with Lung Adenocarcinoma Undergoing Curative Surgery.
CANCERS.
15,
17
(2023)
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non-Small-Cell Lung Cancer.
JOURNAL OF CLINICAL ONCOLOGY.
41,
21
(2023)
Tepotinib Treatment in Patients With MET Exon 14-Skipping Non-Small Cell Lung Cancer Long-term Follow-up of the VISION Phase 2 Nonrandomized Clinical Trial.
JAMA ONCOLOGY.
9,
9
(2023)
A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer.
ESMO OPEN.
8,
3
(2023)
Noncovalent antibody catenation on a target surface greatly increases the antigen-binding avidity.
ELIFE.
12,
(2023)
The prognostic value of radiomic features from pre- and post-treatment 18F-FDG PET imaging in patients with nasopharyngeal carcinoma.
SCIENTIFIC REPORTS.
13,
1
(2023)
Circulating Extracellular-Vesicle-Incorporated MicroRNAs as Potential Biomarkers for Ischemic Stroke in Patients With Cancer.
JOURNAL OF STROKE.
25,
2
(2023)
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
ANNALS OF ONCOLOGY.
34,
3
단행본
(2006)
파종 혈관내 응고증.
군자출판사.
단독
(2006)
혈액학 분양의 DNA Microarray.
E-Pbulic.
단독
학술회의논문
(2017)
NGS를 이용한 Precision Medicine의 구현:현황과 향후 임상연구의 방향.
2017 KCSG Annual Meeting.
대한민국
(2016)
A phase 3, randomized, open-label study of first-line durvalumab (MEDI4736) ± tremelimumab versus standard of care (SoC; EXTREME regimen) in recurrent/metastatic (R/M) SCCHN: KESTREL..
American Society of Clinical Oncology.
미국
(2016)
Phase I study of AZD3759, a CNS penetrable EGFR inhibitor, for the treatment of non-small-cell lung cancer (NSCLC) with brain metastasis (BM) and leptomeningeal metastasis (LM)..
American Society of Clinical Oncology.
미국
(2010)
"Are Those Really the Same Stage?" - Persistent Dilemmas and Controversies of the Revised TNM Staging of Non-Small Cell Lung Cancer and Answers Based on Tertiary Hospital Experience.
Journal of Thoracic Oncology.
대한민국
(2010)
A Double-Blind, Randomized, Parallel, Two-Arm Phase II Trial of BMS-690514 versus Erlotinib in Previous Chemotherapy-Treated Non-Small Cell Lung Cancer (NSCLC) Patients : A Safety Review.
Journal of Thoracic Oncology.
대한민국
(2010)
A Phase II Trial of Neoadjuvant Erlotinib (TARCEVA) Followed by Surgery for Selected Patients with Stage IIIA, N2-Positive Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
EpCAM in Lung Adenocarcinoma Proliferation and Progression.
Journal of Thoracic Oncology.
대한민국
(2010)
Genetic Polymorphisms in Folate Metabolic Pathway Cenes Correlate with Clinical Outcomes in Pemetrexed-Treated Advanced NSCLC Patients..
Journal of Thoracic Oncology.
대한민국
(2010)
Involved Field Radiation Therapy as a Salvage Treatment for Loco-Regional Recurrence after Complete Resection of Non-Small Cell Lung Cancer.
Journal of Thoracic Oncology.
대한민국
(2010)
Outcomes of Surgical N2-Positive Non-Small Cell Lung Cancer Patients Based on Adjuvant Therapy Modality: Single Institute Retrospective Analysis.
Journal of Thoracic Oncology.
대한민국
(2010)
Prognostic Model to Predict Outcomes in Non-Small Cell Lung Cancer Patients with Erlotinib as Salvage Treatment.
Journal of Thoracic Oncology.
대한민국
(2010)
Quantification of Anti-Angiogenic Effect of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKLs) with Dynamic Contrast-Enhanced MR Imaging (DCE-MRI) in Patients with Non-Small Cell Lung Cancer (NSCLC) : Feasibility Study.
Journal of Thoracic Oncology.
대한민국
(2010)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Maintenance for Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Following 1st-Line Platinum-Doublet Chemotherapy.
Journal of Thoracic Oncology.
대한민국
(2010)
Safety and Pharmacokinetics of Interathecal Administration of Pemetrexed in the Rat.
Journal of Thoracic Oncology.
대한민국
(2010)
Targeted Therapy-Related Interstitial Lung Disease: A Case-Based Review.
Journal of Thoracic Oncology.
대한민국
(2010)
The EGFR T790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor.
Journal of Thoracic Oncology.
대한민국
(2010)
Updated Safety and Efficacy Results of a Phase 1/2 Study of PF299804 in Korean Patients with NSCLC Who Experienced Disease Progression on Platinum-Based Chemotherapy Plus Gefitinib or Erlotinib.
Journal of Thoracic Oncology.
대한민국
(2010)
Randomized, Double-Blind, Placebo-Controlled Phase II Study of Vandetanib Maintenance for Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) Following 1st-Line Platinum-Doublet Chemotherapy.
Annals of Oncology.
이탈리아
(2010)
Molecular profiling of pulmonary plemorphic carcinoma: Implications for targeted treatment of a rare lung malignancy..
Journal of Clinical Oncology.
미국
(2010)
PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib(G): A phase (P) I/II study..
Journal of Clinical Oncology.
미국
